DEVELOPMENT OF VACCINIA VIRUS AS AN EXPRESSION VECTOR

痘苗病毒作为表达载体的开发

• 批准号: 6098903
• 负责人: BERNARD MOSS
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6098903
• 关键词: CHO cells; DNA directed RNA polymerase; Paramyxovirus; Primates; bacteriophage T7; cytokine; genetic strain; glycoproteins; interleukin 12; laboratory mouse; laboratory rat; nucleic acid sequence; recombinant virus; transfection /expression vector; vaccine development; vaccinia virus; virus genetics

The cytoplasmic site of gene expression and use of virally encoded enzymes are distinguishing features of vaccinia virus and other poxvirus vectors that contribute to their consistent ability to express genes derived from a variety of prokaryotic, eukaryotic and viral sources. This feature, together with their ability to stably integrate and package large amounts of additional DNA, and broad host range, account for their general use as a research tool and for synthesis of recombinant proteins in mammalian cells. Recombinant vaccinia viruses are also being tested as live vaccines. During the past year, we have been evaluating the highly attenuated modified vaccinia virus Ankara strain as a safe vector in the laboratory and as a vector for candidate vaccines against infectious diseases and cancer.

基因表达的细胞质位点及其用途 病毒编码酶是痘苗病毒的显着特征 和其他有助于其一致能力的痘病毒载体 表达源自多种原核、真核生物的基因 和病毒来源。此功能以及它们稳定的能力 整合并包装大量额外的DNA，并广泛 宿主范围，解释它们作为研究工具的一般用途以及 在哺乳动物细胞中合成重组蛋白。重组 痘苗病毒也正在作为活疫苗进行测试。期间 去年，我们一直在评估高度衰减的改良 痘苗病毒安卡拉株作为实验室的安全载体 传染病候选疫苗的载体和 癌症。